The protective effectiveness of natural rotavirus infection in an american indian population

Journal of Infectious Diseases

Volumn 178, Issue 6, 1998, Pages 1562-1566

  Moulton, Lawrence H ^a   Staat, Mary A ^a   Santosham, Mathuram ^a   Ward, Richard L ^a  

^a Dept of International Health ^*

Author keywords

[No Author keywords available]

Indexed keywords

AMERICAN INDIAN; ANTIBODY TITER; ARTICLE; HOST RESISTANCE; HUMAN; INCIDENCE; INFANT; INFECTION RESISTANCE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; ROTAVIRUS; SEROTYPE; UNITED STATES; VIRUS INFECTION;

ANTIBODIES, VIRAL; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN A; INDIANS, NORTH AMERICAN; INFANT; INFANT, NEWBORN; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; ROTAVIRUS; ROTAVIRUS INFECTIONS; SEROTYPING; TIME FACTORS; UNITED STATES; VIRAL VACCINES;

EID: 0031794769     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314504     Document Type: Article

References (22)

1. Jin S, Kilgore PE, Holman RC, Clarke MJ, Gangarosa EJ, Glass RI. Trends in hospitalizations for diarrhea in U.S. children from 1979 through 1992: estimates of the morbidity associated with rotavirus. Pediatr Infect Dis J 1997;15:397-404.
2. Cook SM, Glass RI, LeBaron CW, Ho MS. Global seasonality of rotavirus infections. Bull World Health Organ 1990;68:171-7.
3. Institute of Medicine. The prospects for immunizing against rotavirus. In: New vaccine development: establishing priorities. Vol 2. Diseases of importance in developing countries. Washington, DC: National Academy Press, 1986:308-18.
4. Bernstein DI, Glass RI, Rodgers G, Davidson BL, Sack DA. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. JAMA 1995;273:1191-6.
5. Perez-Schael I, Guntinas MJ, Perez M, et al. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N Engl J Med 1997;337:1181-7.
6. Santosham M, Moulton LH, Reid R, et al. Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations. J Pediatr 1997;131:632-8.
7. Rennels MB, Glass RI, Dennehy PH, et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines - report of the National Multicenter Trial. Pediatrics 1996;97:7-13.
8. Lanata CF, Midthun K, Black RE, et al. Safety, immunogenicity, and protective efficacy of one and three doses of the tetravalent rhesus rotavirus vaccine in infants in Lima, Peru. J Infect Dis 1996;174:268-75.
9. Linhares AC, Gabbay YB, Mascarenhas JD, et al. Immunogenicity, safety and efficacy of tetravalent rhesus-human, reassortant rotavirus vaccine in Belem, Brazil. Bull World Health Organ 1996;74:491-500.
10. Joensuu J, Koskenniemi E, Pang XL, Vesikari T. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 1997;350:1205-9.
11. Bernstein DI, Sander DS, Smith VE, Schiff GM, Ward RL. Protection from rotavirus reinfection: 2-year prospective study. J Infect Dis 1991;164:277-83.
12. Ukae S, Nakata S, Adachi N, Kogawa K, Chiba S. Efficacy of rhesus rotavirus vaccine MMU-18006 against gastroenteritis due to serotype 1 rotavirus. Vaccine 1994;12:933-9.
13. Bernstein DI, Smith VE, Sander DS, Pax KA, Schiff GM, Ward RL. Evaluation of WC3 rotavirus vaccine and correlates of protection in healthy infants. J Infect Dis 1990;162:1055-62.
14. Linhares AC, Gabbay YB, Mascarenhas JD, et al. Epidemiology of rotavirus subgroups and serotypes in Belem, Brazil: a three-year study. Ann Inst Pasteur Virol 1988;139:89-99.
15. Velazquez FR, Matson DO, Calva JJ, et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996;335:1022-8.
16. Reves RR, Hossain MM, Midthun K, et al. An observational study of naturally acquired immunity to rotaviral diarrhea in a cohort of 363 Egyptian children. Calculation of risk for second episodes using age-specific person-years of observation. Am J Epidemiol 1989;130:981-8.
17. Matson DO, O'Ryan ML, Herrera I, Pickering LK, Estes MK. Fecal antibody responses to symptomatic and asymptomatic rotavirus infections. J Infect Dis 1993;167:577-83.
18. O'Ryan ML, Matson DO, Estes MK, Pickering LK. Anti-rotavirus G type-specific and isotype-specific antibodies in children with natural rotavirus infections. J Infect Dis 1994;169:504-11.
19. Clemens JD, Ward RL, Rao MR, et al. Seroepidemiologic evaluation of antibodies to rotavirus as correlates of the risk of clinically significant rotavirus diarrhea in rural Bangladesh. J Infect Dis 1992:165:161-5.
20. Ward RL, Clemens JD, Knowlton DR, et al. Evidence that protection against rotavirus diarrhea after natural infection is not dependent on serotype-specific neutralizing antibody. J Infect Dis 1992;166:1251-7.
21. Ward RL, Bernstein DI, Young EC, Sherwood JR, Knowlton DR, Schiff GM. Human rotavirus studies in volunteers: determination of infectious dose and serological response to infection. J Infect Dis 1986:154:871-80.
22. Ward RL, McNeal MM, Clemens JD, et al. Reactivities of serotyping monoclonal antibodies with culture-adapted human rotaviruses. J Clin Microbiol 1991;29:449-56.